Rhythm Pharmaceuticals Inc.

Genetic obesity and appetite regulation disorders

Rhythm Pharmaceuticals Inc. focuses on conditions linked to impaired body weight and hunger control, with research centered on obesity driven by specific genetic variants affecting melanocortin pathway signaling.

  • Setmelanotide in genetically defined obesity
  • Body weight change
  • Hunger regulation

The sponsor’s clinical activity is directed toward precision medicine approaches for patients whose obesity is associated with disrupted biological pathways controlling appetite and energy balance.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of Setmelanotide for Patients with Obesity Due to Specific Genetic Variants

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Greece The Netherlands Spain